- Home
- IMCR vs WINA Comparison
IMCR vs WINA Comparison
Compare IMCR & WINA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- WINA
- Stock Information
- Founded
- IMCR 2008
- WINA 1988
- Country
- IMCR United Kingdom
- WINA United States
- Employees
- IMCR N/A
- WINA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- WINA Other Specialty Stores
- Sector
- IMCR Health Care
- WINA Consumer Discretionary
- Exchange
- IMCR Nasdaq
- WINA Nasdaq
- Market Cap
- IMCR 1.5B
- WINA 1.5B
- IPO Year
- IMCR 2021
- WINA 1993
- Fundamental
- Price
- IMCR $36.60
- WINA $424.82
- Analyst Decision
- IMCR Buy
- WINA Strong Buy
- Analyst Count
- IMCR 10
- WINA 1
- Target Price
- IMCR $58.13
- WINA $445.00
- AVG Volume (30 Days)
- IMCR 440.3K
- WINA 74.2K
- Earning Date
- IMCR 05-07-2025
- WINA 07-16-2025
- Dividend Yield
- IMCR N/A
- WINA 2.63%
- EPS Growth
- IMCR N/A
- WINA 2.14
- EPS
- IMCR N/A
- WINA 11.19
- Revenue
- IMCR $333,581,000.00
- WINA $83,099,300.00
- Revenue This Year
- IMCR $25.96
- WINA $6.56
- Revenue Next Year
- IMCR $8.06
- WINA $3.57
- P/E Ratio
- IMCR N/A
- WINA $37.97
- Revenue Growth
- IMCR 25.75
- WINA 0.33
- 52 Week Low
- IMCR $23.15
- WINA $295.79
- 52 Week High
- IMCR $49.05
- WINA $434.87
- Technical
- Relative Strength Index (RSI)
- IMCR 71.46
- WINA 71.17
- Support Level
- IMCR $31.14
- WINA $414.20
- Resistance Level
- IMCR $33.30
- WINA $426.00
- Average True Range (ATR)
- IMCR 1.94
- WINA 10.64
- MACD
- IMCR 0.57
- WINA -0.96
- Stochastic Oscillator
- IMCR 96.12
- WINA 70.95
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.